Dear Editor,Worldwide the incidence of melanoma is increasing faster than of any other cancer. Early
detection is critical in reducing mortality and morbidity, and therefore general
practitioners (GPs) need to be able to screen effectively between benign and suspicious
lesions.[1,2] Interventions that improve the accuracy of secondary
care triaging may be used to prioritize patients with malignant lesions and help combat
the hindrances of long waiting times. GPs referring suspected melanomas to our
department were asked to use a pro forma with an integrated 10-point Likert scoring tool
and grade the likelihood of lesions being melanomas (1 least likely, 10 most likely).
Based on results from a previous pilot study in our department, all patients referred
with a score ≥4 were triaged to an urgent appointment and those with a score of
≤3 to a soon appointment. Our aim was to assess the usefulness of this proforma
in discriminating between malignant melanomas (MM) and other pigmented lesions (NM). We
retrospectively assessed the clinical records of all (n=75) patients diagnosed with MM
in 2016 who were referred using the above proforma and matched them with 75 consecutive
NM patients. Two hundred patients with primary MM were diagnosed in our department in
2016, 75 (37.5%) of which with the above proforma. In the MM group 38 patients were male
and 37 female, with a mean age of 59.8 years. In the NM group, 29 patients were male and
46 female, with a mean age of 48.4 years. Both groups had overlapping scores ranging
from 1 - 10 (Figure 1). Median and mean scores in
the MM group were 6 and 6.02. The NM group had a median score of 5, and mean of 4.78.
There was no statistical difference between the two groups (p=0.97). Forty-one MMs had
Breslow thickness <1mm, 26 between 1-4mm, and eight >4mm. Of the 75 NM lesions, 32
represented benign naevi, 22 seborrheic keratoses, six were pigmented basal cell
carcinomas, and 15 represented a mixture of other benign lesions (Figure 2). Using this proforma and based on a score of 4 as the
cut-off, 78% of all NM lesions and only 80% of MMs would have been given an urgent
appointment. Furthermore, adjusting the cut-off value would not improve the situation
meaningfully. Based on earlier studies, 60-95% of GP referrals of lesions to UK
dermatologists were benign, and GPs could only recognize 66.7% of all skin
malignancies.[3,4] Taking the above into consideration, any triaging tool
that is based on GP scoring is likely to be unsuccessful. Interestingly, recent
developments in the field of artificial intelligence have shown promising results on the
ability of computer programs to accurately recognize and classify cutaneous
tumours.[5] Even though further
research is required for such tools to be widely available, their potential for use on
mobile devices may be key in augmenting the clinical decision-making of GPs and
transforming the referral process.[5]
Until such programs become available it is hard to quantify the effort, resources, and
time required to train GPs and the success of such an undertaking. We therefore argue
that all suspicious pigmented lesions referred to secondary care be triaged as
urgent.
Figure 1
A summary of the scores used to refer both malignant melanoma (MM) and other
pigmented lesions (NM)
Figure 2
A summary of all the non-melanoma lesions that were referred using the
proforma as suspected melanomas
A summary of the scores used to refer both malignant melanoma (MM) and other
pigmented lesions (NM)A summary of all the non-melanoma lesions that were referred using the
proforma as suspected melanomas
Authors: Andre Esteva; Brett Kuprel; Roberto A Novoa; Justin Ko; Susan M Swetter; Helen M Blau; Sebastian Thrun Journal: Nature Date: 2017-01-25 Impact factor: 49.962
Authors: Charles M Balch; Jeffrey E Gershenwald; Seng-Jaw Soong; John F Thompson; Michael B Atkins; David R Byrd; Antonio C Buzaid; Alistair J Cochran; Daniel G Coit; Shouluan Ding; Alexander M Eggermont; Keith T Flaherty; Phyllis A Gimotty; John M Kirkwood; Kelly M McMasters; Martin C Mihm; Donald L Morton; Merrick I Ross; Arthur J Sober; Vernon K Sondak Journal: J Clin Oncol Date: 2009-11-16 Impact factor: 44.544
Authors: P Pockney; J Primrose; S George; N Jayatilleke; B Leppard; H Smith; P Little; R Kneebone; A Lowy Journal: Br J Cancer Date: 2009-01-13 Impact factor: 7.640